StockData

VitaSpring Biomedical Co. Ltd. (VSBC) stock

VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31
Financials through Q2 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 17, 2026Score 4/30
$0.03+0.00 (0.00%)

Close on Oct 19, 2026Market cap $6.58MP/E –Yield –

VitaSpring Biomedical gross margin

Gross margin is gross profit as a percentage of revenue.

VitaSpring Biomedical's gross margin for the twelve months ending Oct 31, 2022 was 40.9%. For fiscal 2022 it was 36.8%, against 45.2% the year before. The highest annual figure on record is 79.8% in fiscal 2019.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2022Jan 31, 202236.8%−8.4
FY2021Jan 31, 202145.2%+34.0
FY2020Jan 31, 202011.2%−68.7
FY2019Jan 31, 201979.8%+10.0
FY2018Jan 31, 201869.9%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q1 FY2023CQ1 2022Apr 30, 202238.1%−6.8
Q4 FY2022CQ4 2021Jan 31, 202242.0%−3.2
Q3 FY2022CQ3 2021Oct 31, 202110.0%+125.0
Q2 FY2022CQ2 2021Jul 31, 202124.5%−62.9
Q1 FY2022CQ1 2021Apr 30, 202144.9%−43.0
Q4 FY2021CQ4 2020Jan 31, 202145.2%−40.1
Q4 FY2020CQ4 2019Jan 31, 2020-115.0%−194.4
Q1 FY2020CQ1 2019Apr 30, 201987.5%+9.3
Q4 FY2019CQ4 2018Jan 31, 201987.9%+11.5
Q3 FY2019CQ3 2018Oct 31, 201885.3%−0.6
Q2 FY2019CQ2 2018Jul 31, 201879.4%+40.3
Q1 FY2019CQ1 2018Apr 30, 201878.2%−6.0
Q4 FY2018CQ4 2017Jan 31, 201876.5%–
Q3 FY2018CQ3 2017Oct 31, 201785.9%–
Q2 FY2018CQ2 2017Jul 31, 201739.1%–
Q1 FY2018CQ1 2017Apr 30, 201784.2%–

More VitaSpring Biomedical figures

See a number that looks wrong?